logo
Borealis expands sustainable foam line in Germany

Borealis expands sustainable foam line in Germany

Fibre2Fashion28-05-2025

Borealis continues to invest in growth through sustainable solutions that are transforming the polymer industry. Its facility in Burghausen, Germany, is significantly expanding production capacity for an innovative polymer foam solution called Daploy High Melt Strength polypropylene (HMS PP). This investment—totaling over EUR 100 million—addresses growing global demand for recyclable, high-performance foam solutions. The new line, scheduled to start up in the second half of 2026, will triple Borealis' supply capability for fully recyclable HMS PP. This expansion enables the transition to more circular and recyclable material solutions for customers in the consumer products, automotive, and building and construction industries.
Borealis is investing over €100 million (~$113.24 million) to triple production of Daploy HMS PP at its Burghausen site by 2026, addressing rising demand for recyclable, high-performance foam. Used in packaging, automotive, and construction, Daploy offers lightweight strength, reduces emissions, and supports circularity. The expansion underscores Borealis' focus on sustainable innovation.
The development of Daploy HMS PP took place at Borealis' Innovation Headquarters in Linz. The new product provides exceptional foamability, lightweight properties, and mechanical strength—characteristics that support material efficiency and help cut both costs and CO2 emissions. It is suitable for use in monomaterial solutions, which are easily recyclable at end of life.
By supporting the sustainability principles of Reduce, Reuse, and Recycle, Daploy HMS PP addresses the growing demand for recyclable solutions across multiple industry segments:
The properties of Daploy HMS PP make it ideal for a wide range of consumer products applications, such as reusable coffee cups and food packaging. As a lightweight, recyclable material that supports reuse, it helps packaging producers meet the requirements of the EU Packaging and Packaging Waste Regulation (PPWR).
In the automotive industry, Daploy is used for ultra-lightweight foamed interior and under-the-hood components. Typically 60-90% lighter than non-foamed alternatives, these components help improve fuel efficiency and reduce carbon emissions. It also enables zero-waste production as all production trim-offs can be easily recycled. In addition, Daploy makes it possible for these parts to be constructed from a single material, facilitating recycling at the end of the vehicle's life.
In the building and construction sector, Daploy HMS PP is used to replace heavier materials in insulation and paneling applications. Its durability, strength, and heat resistance ensure excellent performance, while its lightweight properties and recyclability improve the sustainability of these components.
The expansion is another example of Borealis' dedication to delivering innovative, high-quality products that advance sustainability, and reinforces its leadership in the PP market.
'In line with our We4Customers strategy, this investment creates value for customers by enabling them to design recyclable, foam-based products for a wide range of high-performance applications,' explains Craig Arnold, Borealis Executive Vice President Polyolefins, Circular Economy Solutions and Base Chemicals. 'By expanding production, we're ensuring a reliable supply of this advanced material to help our customers achieve their sustainability goals and deliver high-performance solutions.
Visitors to K 2025 will have the opportunity to explore a range of Daploy HMS PP solutions at the Borealis and Borouge stand Hall 6, Stand A43, and discuss how these grades can help them meet their sustainability and performance goals. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (HU)

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane

Business Standard

timean hour ago

  • Business Standard

Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane

Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.

OneSource collaborates with Xbrane Biopharma AB
OneSource collaborates with Xbrane Biopharma AB

Business Standard

time4 hours ago

  • Business Standard

OneSource collaborates with Xbrane Biopharma AB

For commercial manufacturing of Xbrane's biosimilar portfolio OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource's state-of the-art integrated Drug Substance and Drug Product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbrane's global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbrane's latest funding round, reinforcing the long-term alignment between the two companies.

EUR/USD off six-week high after ECB rate cut
EUR/USD off six-week high after ECB rate cut

Business Standard

time5 days ago

  • Business Standard

EUR/USD off six-week high after ECB rate cut

EUR/USD pair is currently quoting at 1.1420, almost unchanged on the day. It came off a six-week high above 1.1500 yesterday after European Central Bank reduced its key interest rate by 25 basis points to 2% - its lowest level since early 2023. On the NSE, EUR/INR futures are quoting at 98.09, down marginally on the day after hitting 98.50 mark in early moves. Meanwhile, German industrial output declined 1.4% month-on-month in April, in contrast to the 2.3% increase in March, marking the biggest fall since December.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store